Schizophrenia 2 -Preclinical

[P158] Orphan GPCRs – a new frontier in schizophrenia drug discovery

*Greg Stewart^1,2, Yao Lu¹, Sheng Yu Ang^1,2, Daisy Spark^2,3, Juulke Castelijn^2,3, Trang Pham^2,4, Michelle Camerino^2,4, Monica Langiu¹, Natalie Diepenhorst¹, Clotilde Mannoury La Cour⁵, Leonid Churilov⁶, Jess Nithianantharajah^2,3, Chris Langmead^1,2 (1. Drug Discovery Biology, Neuromedicines Discovery Centre, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia, 2. Phrenix Therapeutics, Parkville, Victoria, Australia, 3. The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia, 4. Australian Translational Medicinal Chemistry Facility, Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia, 5. Les Laboratoires Servier, Suresnes, Paris, France, 6. Melbourne Medical School, The University of Melbourne, Parkville, Victoria, Australia)

Keywords:Schizophrenia, Drug discovery, Orphan GPCRs